CellMax Life Launches With $14M in Funding, Early Colorectal Cancer Detection Test | GenomeWeb

NEW YORK (GenomeWeb) – Blood-based cancer testing firm CellMax Life officially launched today having raised $9 million in series A-1 venture financing, which — combined with earlier investments — brings its total funds raised to date to $14 million.

The $9 million funding round was led by Silicon Valley venture capital firm Artiman, as well as several Taiwanese venture investors including Acer Founder and Chairman Stan Shih, CellMax said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.

Sponsored by

This webinar will discuss a partnership model for noninvasive prenatal testing that enabled LifeLabs Genetics, a genetic testing lab based in Toronto, Ontario, to implement NIPT in house.